110 related articles for article (PubMed ID: 32552992)
1. Examining the cost of community-based tuberculosis treatment in South Africa.
Moran A; Kula N; Jagwer G; Broughton E; Pillay Y; Mvusi L; AlMossawi H; Ndjeka N; Mametja D; Dlamini C; Ahmedov S; Matji R; Kak N
Int J Tuberc Lung Dis; 2020 Jun; 24(6):612-618. PubMed ID: 32552992
[No Abstract] [Full Text] [Related]
2. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
3. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?
Pooran A; Pieterson E; Davids M; Theron G; Dheda K
PLoS One; 2013; 8(1):e54587. PubMed ID: 23349933
[TBL] [Abstract][Full Text] [Related]
4. Time-to-Treatment Initiation in a Decentralised Community-Care Model of Drug-Resistant Tuberculosis Management in the OR Tambo District Municipality of South Africa.
Iruedo JO; Pather MK
Int J Environ Res Public Health; 2023 Jul; 20(14):. PubMed ID: 37510655
[TBL] [Abstract][Full Text] [Related]
5. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
[TBL] [Abstract][Full Text] [Related]
6. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
[TBL] [Abstract][Full Text] [Related]
7. MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care.
Loveday M; Wallengren K; Reddy T; Besada D; Brust JCM; Voce A; Desai H; Ngozo J; Radebe Z; Master I; Padayatchi N; Daviaud E
PLoS One; 2018; 13(4):e0196003. PubMed ID: 29668748
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
9. Lived experiences of patients and families with decentralised drug-resistant tuberculosis care in the Eastern Cape, South Africa.
Iruedo JO; Pather MK
Afr J Prim Health Care Fam Med; 2023 Dec; 15(1):e1-e16. PubMed ID: 38197684
[TBL] [Abstract][Full Text] [Related]
10. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa.
van Rensburg C; Berhanu R; Hirasen K; Evans D; Rosen S; Long L
PLoS One; 2019; 14(6):e0217820. PubMed ID: 31170207
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa.
Floyd K; Wilkinson D; Gilks C
BMJ; 1997 Nov; 315(7120):1407-11. PubMed ID: 9418087
[TBL] [Abstract][Full Text] [Related]
12. Loss from treatment for drug resistant tuberculosis: risk factors and patient outcomes in a community-based program in Khayelitsha, South Africa.
Moyo S; Cox HS; Hughes J; Daniels J; Synman L; De Azevedo V; Shroufi A; Cox V; van Cutsem G
PLoS One; 2015; 10(3):e0118919. PubMed ID: 25785451
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013.
Chingonzoh R; Manesen MR; Madlavu MJ; Sopiseka N; Nokwe M; Emwerem M; Musekiwa A; Kuonza LR
PLoS One; 2018; 13(8):e0202469. PubMed ID: 30133504
[TBL] [Abstract][Full Text] [Related]
14. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis.
Masuku SD; Berhanu R; Van Rensburg C; Ndjeka N; Rosen S; Long L; Evans D; Nichols BE
Int J Tuberc Lung Dis; 2020 Apr; 24(4):376-382. PubMed ID: 32317060
[TBL] [Abstract][Full Text] [Related]
15. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
16. When students become patients: TB disease among medical undergraduates in Cape Town, South Africa.
Van der Westhuizen HM; Dramowski A
S Afr Med J; 2017 May; 107(6):475-479. PubMed ID: 28604316
[TBL] [Abstract][Full Text] [Related]
17. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa.
Heller T; Lessells RJ; Wallrauch CG; Bärnighausen T; Cooke GS; Mhlongo L; Master I; Newell ML
Int J Tuberc Lung Dis; 2010 Apr; 14(4):420-6. PubMed ID: 20202299
[TBL] [Abstract][Full Text] [Related]
18. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
[TBL] [Abstract][Full Text] [Related]
19. Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa.
Sinanovic E; Floyd K; Dudley L; Azevedo V; Grant R; Maher D
Int J Tuberc Lung Dis; 2003 Sep; 7(9 Suppl 1):S56-62. PubMed ID: 12971655
[TBL] [Abstract][Full Text] [Related]
20. Cost of treatment for multidrug-resistant tuberculosis in South Korea.
Kang YA; Choi YJ; Cho YJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Respirology; 2006 Nov; 11(6):793-8. PubMed ID: 17052310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
